BRIEF — Vanda Pharmaceuticals Provides Update On Vqw — 765 Clinical Development Program
Oct 14 (Reuters) — Vanda Pharmaceuticals Inc: Vanda Pharmaceuticals Provides Update On Vqw-765 Clinical Development Program Vanda Pharmaceuticals - Phase Iii Study Of Vqw-765 Did Not Meet Primary Endpoint In Social Anxiety Disorder Vanda Pharmaceuticals - Vqw-765 Found Safe And Well Tolerated In Phase Iii Study Vanda P